Glenmark Generics Inc., USA (GGI), a subsidiary of Glenmark Generics Limited (GGL), received ANDA approval from the United States Food and Drug Administration (USFDA) for Adapalene Gel, 0.1% and will soon commence marketing and distribution of this product in the US market. The company anticipates a successful launch based on their semi-solid experience and the limited number of competitors in this market.

Adapalene Gel is indicated for the topical treatment of acne vulgaris. Glenmark’s product is the AB rated generic equivalent of Galderma’s Differin gel which generated approximately $84 million in sales for the 12-month period ending March 2010, according to IMS Health.

Glenmark’s current portfolio consists of 55 products authorized for distribution in the US marketplace.

The Company has over 50 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Check out these stories also:

1. Glenmark gets USFDA nod for oral contraceptive drug Briellyn
2. Glenmark gets final USFDA nod for skin infection ointment
3. USFDA gives nod to Glenmark Generics’ 3 abbreviated new drug application
4. USFDA gives nod for Glenmark Generics’ Norethindrone contraceptive tablets
5. Glenmark Generics’ Verapamil SR tablets receives ANDA approval

Custom Search